Efficacy and tolerability of 1.6% phenol-croton peeling vs. topical 5% imiquimod in the treatment of actinic cheilitis: a randomized controlled trial

被引:0
|
作者
Garbers, Luiz Eduardo Fabricio de Melo [1 ]
Miola, Anna Carolina [1 ]
de Souza, Vinicius [1 ]
Brommonschenkel, Christina de Castro [1 ]
Lima, Flavio de Oliveira [1 ]
Minicucci, Eliana Maria [1 ]
Miot, Helio Amante [1 ]
机构
[1] UNESP, Fac Med Botucatu, Med Sch, Botucatu, SP, Brazil
关键词
SQUAMOUS-CELL CARCINOMA; PHOTODYNAMIC THERAPY; CREAM;
D O I
10.1093/ced/llae520
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background Trials evaluating the effectiveness of topical treatments for actinic cheilitis (AC) are scarce. Despite no comparative data, phenol-croton peeling has been reported as effective in treating this condition. Objective To assess for the treatment of AC the efficacy and tolerability of a single session of 1.6% phenol-croton peeling vs. topical 5% imiquimod cream applied for 30 days for the treatment of AC. Methods An open, randomized controlled trial was conducted to compare the effectiveness and tolerability of 1.6% phenol-croton peeling vs. topical 5% imiquimod for the treatment of AC [protocol registered at ReBEC (Brazilian Registry of Clinical Trials) - RBR-1044sz68]. Thirty-six patients with biopsy-proven AC were allocated into two groups (1 : 1): the imiquimod group received 5% topical imiquimod three times a week for 30 days, and the croton group underwent one session of 1.6% phenol-croton peeling. The primary outcome was the clearance of AC after 56 days. Secondary outcomes included clinical and histological parameters, adverse effects and clinical results after 180 days. Results Complete clinical clearance of AC (defined as clearance of both leukoplakia and hyperkeratosis) at day 56 and day 180 occurred in 17 of 18 (94%) participants from the croton group but in none of the 18 participants in the imiquimod group (P < 0.01). Improvement in all clinical parameters was more prominent in the croton group (P <= 0.01). Complete histological normalization at day 56 occurred in 72% of the croton group and only 17% in the imiquimod group (P < 0.01). Histological parameters such as atypia (keratinocyte intraepithelial neoplasia score), solar elastosis and hyperkeratosis reduced in intensity only in the croton group (P < 0.05). Adverse effects were most intense on day 7 in the croton group and persisted until day 21 in the imiquimod group. The study was prematurely terminated at the interim analysis. Conclusions A single session of 1.6% phenol-croton peeling produced clinically and histologically superior results with a shorter recovery period compared with imiquimod for treating AC.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] 5% lidocaine medicated plaster vs pregabalin in patients with painful diabetic polyneuropathy (DPN): efficacy and tolerability results from a randomized, controlled trial
    Baron, R.
    Nell, G.
    Steigerwald, I.
    Rogers, P. D.
    DIABETOLOGIA, 2009, 52 : S452 - S452
  • [32] Three-Year Follow-Up Results of Photodynamic Therapy vs. Imiquimod vs. Fluorouracil for Treatment of Superficial Basal Cell Carcinoma: A Single-Blind, Noninferiority, Randomized Controlled Trial
    Roozeboom, Marieke H.
    Arits, Aimee H. M. M.
    Mosterd, Klara
    Sommer, Anja
    Essers, Brigitte A. B.
    de Rooij, Michette J. M.
    Quaedvlieg, Patricia J. F.
    Steijlen, Peter M.
    Nelemans, Patty J.
    Kelleners-Smeets, Nicole W. J.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (08) : 1568 - 1574
  • [33] Treatment of superficial basal cell carcinoma by topical photodynamic therapy with fractionated 5-aminolaevulinic acid 20% vs. two-stage topical methyl aminolaevulinate: results of a randomized controlled trial
    Kessels, J. P. H. M.
    Kreukels, H.
    Nelemans, P. J.
    Roozeboom, M. H.
    van Pelt, H.
    Mosterd, K.
    de Haas, E. R. M.
    Kelleners-Smeets, N. W. J.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (05) : 1056 - 1063
  • [34] Efficacy and safety of topical isobutylamido thiazolyl resorcinol (Thiamidol) vs. 4% hydroquinone cream for facial melasma: an evaluator-blinded, randomized controlled trial
    Lima, P. B.
    Dias, J. A. F.
    Cassiano, D. P.
    Esposito, A. C. C.
    Miot, L. D. B.
    Bagatin, E.
    Miot, H. A.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (09) : 1881 - 1887
  • [35] A prospective randomized exploratory study comparing the efficacy of once-daily topical 0.5% 5-fluorouracil in combination with 10.0% salicylic acid (5-FU/SA) vs. cryosurgery for the treatment of hyperkeratotic actinic keratosis
    Simon, J. -C.
    Dominicus, R.
    Karl, L.
    Rodriguez, R.
    Willers, C.
    Dirschka, T.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2015, 29 (05) : 881 - 889
  • [36] Efficacy, safety and tolerability of formula-based unilateral vs bilateral electroconvulsive therapy in the treatment of major depression: A randomized open label controlled trial
    Dominiak, Monika
    Antosik-Wojcinska, Anna Z.
    Goetz, Zuzanna
    Sikorska, Olga
    Stefanowski, Bogdan
    Gorostiza, Dagny
    Swiecicki, Lukasz
    JOURNAL OF PSYCHIATRIC RESEARCH, 2021, 133 : 52 - 59
  • [37] Efficacy and safety of methotrexate plus hydroxychloroquine combination therapy vs. methotrexate monotherapy in the treatment of rheumatoid arthritis: A randomized controlled clinical trial
    Ma, Jiasheng
    Zeng, Miaoyu
    Hsu, Chi-Jen
    Li, Dandan
    Fok, Mei Na
    Jiang, Yan
    Li, Qiaoqiao
    Ma, Jie
    Zhou, Jiaze
    Chen, Brian Shiian
    Li, Fengju
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2024, 27 (09)
  • [38] Comparative efficacy of topical 10% versus 5% tranexamic acid in treatment of women with melasma: a double-blind randomized controlled trial
    Mawu, Ferra Olivia
    Kapantow, Marlyn Grace
    Pandaleke, Herry E. J.
    Cahyadi, Alexandro Ivan
    Togelang, Lidya
    Tampi, Joan Alexandra
    Christopher, Paulus Mario
    UNIVERSA MEDICINA, 2024, 43 (02) : 213 - 219
  • [39] An open label, randomized clinical trial to compare the tolerability and efficacy of ivermectin plus diethylcarbamazine and albendazole vs. diethylcarbamazine plus albendazole for treatment of brugian filariasis in Indonesia
    Supali, Taniawati
    Djuardi, Yenny
    Christian, Michael
    Iskandar, Elisa
    Alfian, Rahmat
    Maylasari, Roospita
    Destani, Yossi
    Lomiga, Adriani
    Minggu, Dominikus
    Lew, Daphne
    Bogus, Joshua
    Weil, Gary J.
    Fischer, Peter U.
    PLOS NEGLECTED TROPICAL DISEASES, 2021, 15 (03):
  • [40] Efficacy, safety, tolerability, and satisfaction of N-acetylcysteine and pentoxifylline in lichen planopilaris patients under treatment with topical clobetasol: A triple arm blinded randomized controlled trial
    Kahjoogh, Hossein Ahmadi
    Yazdanian, Nafise
    Behrangi, Elham
    Roohaninasab, Masoumeh
    Hejazi, Pardis
    Goodarzi, Azadeh
    DERMATOLOGIC THERAPY, 2022, 35 (08)